Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555

British Journal of Pharmacology

Volumn 125, Issue 8, 1998, Pages 1708-1714

  Upton, R ^a   Widdowson, P S ^a   Ishii, S ^b   Tanaka, H ^b   Williams, G ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b MITSUBISHI CHEMICAL CORPORATION   (Japan)

Author keywords

Diabetes; MCC 555; Metabolism; Obese (fa fa) Zucker rats; Thiazolidinedione

Indexed keywords

FATTY ACID; GLUCOSE; GLYCOGEN SYNTHASE; INSULIN; NETOGLITAZONE; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; ENZYME ACTIVITY; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLUCOSE TOLERANCE; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; MALE; METABOLISM; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT;

ANIMALS; BASAL METABOLISM; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; FATTY ACIDS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIVER GLYCOGEN; MALE; OBESITY; RATS; RATS, ZUCKER; THIAZOLES; THIAZOLIDINEDIONES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0032406145     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702245     Document Type: Article

References (30)

1. BÄHR, M., SPELLEKEN, M., BOCK, M., VON HOLTEY, M., KIEHN, R. & ECKEL, J. (1996). Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes. Diabetologia, 39, 766-774.
2. BOWEN, L., STEVEN, P.P., STEVENSON, R. & SCHULMAN, C.I. (1991). The effect of CP-68772, a thiazolidine derivative, on insulin sensitivity in lean and obese Zucker rats. Metabolism, 40, 1025-1030.
3. CLARK, J.B. & PALMER, C.J. (1982). The diabetic Zucker rat - a new model for non-insulin dependent diabetes. Diabetes, 30, 126A.
4. DEFRONZO, R. (1988). The triumvirate: beta cell, muscle, liver. A collusion responsible for NIDDM. Diabetes, 37, 667-685.
5. DESOUZA, C.J., YU, J.H., ROBINSON, D.D., ULRICH, R.G. & MEGLASSON, M.D. (1995). Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance. Diabetes, 44, 984-991.
6. ELDERSHAW, T.P.D., RATTIGAN, S., CAWTHORNE, M.A., BUCKINGHAM, R.E., COLQUHOUN, E.Q. & CLARK, M.G. (1995). Treatment with the thiazolidinedione (BRL 49653) decreases insulin resistance in obese Zucker hindlimb. Hormone Metab. Res., 21, 169-172.
7. FOLCH, J., LEES, M. & STANLEY, G.H.S. (1956). A simple method for the isolation and purification of total lipids from animal tissue. J. Biol. Chem., 273, 497-509.
8. 2 is a ligand for the adipocyte determination factor PPAR-gamma. Cell, 83, 803-812.
9. HARRIS, M.I. (1996). Impaired glucose tolerance prevalence and conversion to NIDDM. Diabetes Med., 13 (3 suppl 2), S9-S11.
10. HIRSHMAN, M.F., FAGNANT, P.M., HORTON, E.D., KING, P.A. & HORTON, E.S. (1995). Pioglitazone treatment for 7 days failed to correct the defect in glucose transport and glucose transporter translocation in obese Zucker (fa/fa) skeletal muscle plasma membranes. Biochem. Biophys. Res. Commun., 208, 835-845.
11. ISHII, S., WASAKI, M., OHNE, T., UENO, H. & TANAKA, H. (1996). MCC-555: A highly potent thiazolidinedione lacking hematological and cardiac side-effects. Diabetes, 45 Suppl. 2, P141A.
12. 14C-labelled glucose. Biochem. J., 142, 171-174.
13. KUMAR, S., BOULTON, A.J.M., BECK-NIELSEN, H., BERTEZENE, F., MUGGEO, M., PERSON, B., SPINAS, G.A., DONOGHUE, S., LETTIS, S. & STEWART-LONG, P. (1996). Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia, 39, 701-709.
14. LEHMANN, J.M., MOORE, L.B., SMITH-OLIVER, T.A., WILKINSON, W.O., WILSON, T.M. & KLIEWER, S.A. (1995). An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma). J. Biol. Chem., 270, 12953-12956.
15. LOWRY, O.H. (1972). In: A flexible system f enzymatic analysis. Eds. O.H. Lowry & J.V. Pasienneau. pp 180-191. New York, Academic Press.
16. MASUDA, K., OKAMTO, Y., TSUURA, Y., KATO, S., MIURA, T., TSUDA, K., HORIKOSHI, H., ISHIDA, H. & SEINO, Y. (1995). Effects of troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia, 38, 24-30.
17. NOLAN, J.J., LUDVIK, B., BEERDSEN, P., JOYCE, M. & OLEFSKY, J. (1994). Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med., 331, 1188-1193.
18. OAKES, N.D., KENNEDY, C.J., JENKINS, A.B., LAYBULF, D.R., CHISHOLM, D.J. & KRAEGEN, E.W. (1994). A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes, 43, 1203-1210.
19. PETERSON, R.G. (1994). The Zucker diabetic fatty (ZDF) rat. In: Lessons from animal diabetes. ed. Shafrir E. pp 225-230. U.K: Smith-Gordon.
20. RANDLE, P.J., NEWSHOLME, E.A. & GARLAND, P.B. (1964). Regulation of glucose uptake by muscle. Effects of fatty acids, ketone bodies, pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscle. Biochem J., 93, 652-665.
21. SCHMITZ-PEIFFER, C., OAKES, N.D., BROWNE, C.L., KRAEGEN, E.W. & BIDEN, T.J. (1997). Reversal of chronic alterations of skeletal muscle protein kinase C from fat-fed rats by BRL-49653. Am. J. Physiol., 273, E915-E921.
22. SMITH, S.A., LISTER, C.A., HUGHES, M.G., & BUCKINGHAM, R.E. (1997). The PPARgamma agonist, BRL 49653, prevents progression to diabetes in Zucker Diabetic fatty rats. Diabetologia, 4 (suppl. 1), A46.
23. SREENAN, S., STURIS, J., PUGH, W., BURANT, C.F. & POLONSKY, K.S. (1996). Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. Am. J. Physiol., 271, E742-E747.
24. STURGIS, J., PUGH, W.L., TANG, J. & POLONSKY, K.S. (1995). Prevention of diabetes does not completely prevent insulin secretory defects in the ZDF rat. Am. J. Physiol., 269, E786-E792.
25. SUTER, S.L., NOLAN, J.S., WALLACE, P., GUMBINER, B. & OLEFSKY, J.M. (1992). Metabolic effects of a new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care, 15, 193-203.
26. TERRETTAZ, J. & JEANRENAUD, B. (1983). In vivo hepatic and peripheral insulin resistance in genetically obese (fa/fa) rats. Endocrinology, 112, 1346-1351.
27. 14C-glucose. Analyt. Chem., 25, 487-499.
28. WANG, Q., DRYDEN, S., FRANKISH, H.M., BING, C., PICKAVANCE, L., HOPKlNS, D., BUCKINGHAM, R. & WILLIAMS, G. (1997). The thiazolidinedione BRL49653 increases feeding in fatty Zucker rats independently of leptin and hypothalamic neuropeptide Y neurons. Brit. J. Pharmacol., 122, 1405-1410.
29. WILLIAMS, G. (1994). Management of NIDDM. Lancet, 343, 95 100.
30. WILSON, T.M., COBB, J.E., COWAN, D.J., WIETHE, R.W., CORREA, I.D., PRAKASH, S.R., BECK, K.D., MOORE, L.B., KLIEWER, S.A & LEHMANN, J.M. (1996). The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antidiabetic activity of thiazolidinediones. J. Med. Chem., 39, 665-668.